A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

Journal of Virology

Volumn 74, Issue 9, 2000, Pages 4414-4419

  Ziermann, Rainer ^a   Limoli, Kay ^a   Das, Kalyan ^b   Arnold, Edward ^b   Petropoulos, Christos J ^a   Parkin, Neil T ^a,c  

^a MONOGRAM BIOSCIENCES   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE; RITONAVIR; SAQUINAVIR;

ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL ARTICLE; CROSS RESISTANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; SALVAGE THERAPY; SITE DIRECTED MUTAGENESIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTI-HIV AGENTS; CARBAMATES; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; SULFONAMIDES;

EID: 0034002883     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.9.4414-4419.2000     Document Type: Article

References (24)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, M. Duran, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999 HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
3. Carpenter, C. C. J., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1998. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA panel. JAMA 280:78-86.
4. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
5. Gong, Y.-F., B. S. Robinson, R. E. Rose, C. Deminie, T. P. Spicer, D. Stock, R. J. Colonno, and P.-F. Lin. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother., in press.
6. Hecht, F. M., R. M. Grant, C. J. Petropoulos, B. Dillon, M. A. Chesney, H. Tian, N. S. Hellmann, N. I. Bandrapalli, L. Digilio, B. Branson, and J. O. Kahn. 1998. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N. Engl. J. Med. 339:307-311.
7. Hirsch, M. S., B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vezient, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, C. Loveday, J. W. Mellors, S. Vella, and D. D. Richman. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 279:1984-1991.
8. Kim, E. E., C. T. Baker, M. D. Dwyer, M. A. Murcko, B. G. Rao, R. D. Tung, and M. A. Navia. 1995. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1181-1182.
9. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995 Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:695-699.
10. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J. Infect. Dis. 175:1063-1070.
11. Little, S., E. Daar, R. D'Aquila, P. Keiser, E. Connick, J. Whitcomb, N. Hellmann, C. Petropoulos, J. Pitt, E. Rosenberg, R. Koup, and D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
12. Livingston, D., S. Pazhanisamy, D. Porter, J. Partaledis, R. Tung, and G. Painter. 1995. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172:1238-1245.
13. Murphy, R., R. Gulick, V. DeGruttola, R. D'Aquila, J. Eron, J. Sommadossi, J. Currier, L. Smeaton, I. Frank, A. Caliendo, J. Gerber, R. Tung, and D. Kuritzkes. 1999. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J. Infect. Dis. 179:808-816.
14. Palmer, S., R. W. Shafer, and T. C. Merigan. 1999. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 13:661-667.
15. Parkin, N., Y. Lie, N. Hellmann, M. Markowitz, S. Bonhoeffer, D. Ho, and C. Petropoulos. 1999. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J. Infect. Dis. 180:865-870.
16. Partaledis, J. A., K. Yamaguchi, M. Tisdale, E. E. Blair, C. Falcione, B. Maschera, R. E. Myers, S. Pazhanisamy, O. Futer, A. B. Cullinan, C. M. Stuver, R. A. Byrn, and D. J. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
17. Patick, A. K., M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. R. Kuritzkes, and M. Markowitz. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:2637-2644.
18. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, M. T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. Capon, and J. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
19. Sadler, B. M., C. D. Hanson, G. E. Chittick, W. T. Symonds, and N. S. Roskell. 1999. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-intected adults. Antimicrob. Agents Chemother. 43:1686-1692.
20. Sarkar, G., and S. S. Sommer. 1990. The "megaprimer" method of site-directed mutagenesis. BioTcehniques 8:404-407.
21. Schinazi, R. F., B.A. Larder, and J. W. Mellors. 1999. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 7:46-69.
22. Smidt, M. L., K. E. Potts, S. P. Tucker, L. Blystone, T. R. Stiebel, Jr., W. C. Stallings, J. J. McDonald, D. Pillay, D. D. Richman, and M. L. Bryant. 1997. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob. Agents Chemother. 41:515-522.
23. St. Clair, M. H., J. Millard, J. Rooney, M. Tisdale, N. Parry, B. M. Sadler, M. R. Blum, and G. Painter. 1996. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antivir. Res. 29: 53-56.
24. Tucker, S. P., T. R. Stiebel, Jr., K. E. Potts, M. L. Smidt, and M. L. Bryant. 1998. Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro. Antimicrob. Agents Chemother. 42:478-480.